<DOC>
	<DOCNO>NCT01435460</DOCNO>
	<brief_summary>This study evaluate safety efficacy Alrex ( LE ophthalmic suspension , 0.2 % ) versus Patanol ( olopatadine hydrochloride ophthalmic solution , 0.1 % ) temporary relief sign symptoms Seasonal Allergic Conjunctivitis ( SAC ) .</brief_summary>
	<brief_title>AlrexÂ® Versus Patanol Treatment Seasonal Allergic Conjunctivitis ( SAC )</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects diagnose acute SAC experience least grade 4 ocular itch least grade 2 bulbar conjunctival injection ( redness ) eye due seasonal allergy Visit 1 . Subjects know hypersensitivity study medication component contraindication ocular corticosteroid . Subjects use disallow medication throughout duration study period indicate prior Visit 1 . Subjects intraocular pressure ( IOP ) great 21 mm Hg either eye type glaucoma . Subjects history severe/serious ocular pathology medical condition could result subject 's inability complete study affect subject 's safety trial parameter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>ocular allergy</keyword>
</DOC>